Our Risk-Adjusted Asset Portfolio is the Foundation for Future Value Creation

Turning top-tier science into differentiated oncology assets with real patient impact. Cumulus’s approach to portfolio build is based on a platform-agnostic, data and milestone-driven prioritisation process. The focus on enriching for successful outcomes on each program offers optionality and key exit points for the individual programs. This drives value and returns for investors.

Transforming Oncology Drug Development Risk-Reward for Better Patient Outcomes

Cumulus is focussed on improving the success rates in drug discovery and development and translating a portfolio of preclinical-stage assets through into later stage success in the clinic, embedding a precision, patient-focused development strategy for programs at the outset, to drive successful outcomes.

The portfolio is further de-risked by taking a platform-agnostic approach pairing targets that have high-value creation potential with a range of enabling platform technologies. The focus on data-driven, milestone-based decision making, enriches the company’s portfolio with assets that are increasingly weighted towards a successful outcome.

This proactive portfolio management is enhanced by the asset search and curation activities of the company to expand the portfolio and further spread the risk. This approach avoids platform or modality bias and is designed for improved success rates and risk reduction.

I’ve seen too many promising drugs fail – not because they didn’t work, but because they were tested in the wrong patients.”

Clare Wareing, CEO Cumulus Oncology

Asset Curation: Proactively Managing our Asset Portfolio to Drive Value Creation

A Proactive Asset Curation Function is Central to our Portfolio Build and Management

Our structured, network-led sourcing model identifies overlooked opportunities. Key features of our asset curation approach include internal ideation and external validation of targets and assets of interest. This is coupled with proactive asset searching and strategic alliances with leading drug discovery partners.

Expansion Through Proactive Partnering and Licensing

We proactively expand our pipeline with externally sourced assets that can be developed in patient subgroups with distinct vulnerabilities and a defined unmet medical need. Assets and targets are defined and sourced through our approach to asset curation, which is both proactive and opportunistic and based on our extensive network and track record in oncology drug discovery and development.

The Risk-Adjusted Asset Portfolio is the Foundation for Future Value Creation

Our current asset portfolio is a result of our ongoing asset curation and prioritisation efforts. It consists of a pipeline which spreads risk and increases the chances of success by focusing on both validated and more novel targets where defined patient populations with existing unmet medical needs are the commercial focus.

Shaped for Value Creation and Exits

Cumulus manages risk and reward by adopting an asset portfolio curation approach, which includes data-driven, milestone-based decision making and by continually assessing market fit and exit potential via M&A and/or partnering activities with Pharma companies.

Our Programs: A Risk-Adjusted Portfolio of Assets

Cumulus Oncology’s pipeline exemplifies our commitment to advancing differentiated, cancer therapeutics for defined patient populations where a high unmet medical need exists. Through our asset curation approach, we identify and support novel assets targeting key vulnerabilities in defined patient populations. Each asset is considered strategically within our portfolio to both spread risk and optimize the opportunities for successful outcomes. This in turn drives value creation and exit opportunities. Below is an overview of our current portfolio, highlighting the development stage and scientific and clinical target for each program.

Our Multi-Disciplinary Team is Crucial to Our Success

Dr Clare Wareing

Founder & CEO

Clare Doris

Chief Development Officer

James Fair

Chief Financial Officer

Contact Us

For more information on our pipeline or individual programmes please get in touch with us